DT&CRO Co. Ltd. (383930) fair value: what the stock is really worth
As of Oct 6, 2026: fair value of DT&CRO Co. Ltd. KRW 1,163, price KRW 1,918, upside -39.4%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea.
Show more
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.
Stock analysis
DT&CRO Co. Ltd. (383930) currently trades at 1,918 KRW, while our model-based Fair Value estimate is 1,163 KRW, 39.4% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 867.64 KRW (bear) to 1,735 KRW (bull), the price of 1,918 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DT&CRO Co. Ltd. reported revenue of 47.7B KRW in FY2025 versus 32.7B KRW in FY2021, a compound +9.9%/yr. Reported net income was −2.8B KRW in FY2025.
Key figures
Market cap 24.5B KRW (≈ $18.3M) · P/S ratio 0.51 · Net margin −5.8% · Return on equity −105% · Return on assets (EBIT) −3.8% · Operating margin −58.1% · Revenue (TTM) 49.0B KRW · Revenue growth (YoY) +12.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −39%, 383930 screens richer than that median.
Fair Value models
Bear 867.64 KRWFair Value 1,163 KRWBull 1,735 KRW
Price 1,918 KRW · Upside -39.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.0% (2021) → −12.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−39.4% · Above median
Profitability
Return on assets−7.5% · Above median
Net margin (TTM)−34.9% · Bottom 25%
Operating margin (TTM)−58.1% · Bottom 25%
Growth and dividend
Revenue growth12.3% · Above median
Balance sheet
Debt / equity0.51× · Highest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)62· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)75· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DT&CRO Co. Ltd. (383930) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 1,163 KRW versus a price of 1,918 KRW, about −39% upside (overvalued).
What is the fair value of 383930?
Our model-based fair value for DT&CRO Co. Ltd. is 1,163 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 1,918 KRW.
What is the quality score of 383930?
DT&CRO Co. Ltd. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DT&CRO Co. Ltd. (383930)?
Our model-based price target is the fair value of 1,163 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 867.64 KRW, optimistic scenario 1,735 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DT&CRO Co. Ltd. stock forecast for 2026?
Our models put fair value at 1,163 KRW, about −39% upside versus a price of 1,918 KRW (overvalued). Cautious scenario 867.64 KRW, optimistic scenario 1,735 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DT&CRO Co. Ltd. (383930)?
DT&CRO Co. Ltd. reported trailing-twelve-month revenue of about 49.0B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of DT&CRO Co. Ltd. (383930)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DT&CRO Co. Ltd. it is 1,163 KRW per share (as of Oct 3, 2026), against a price of 1,918 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is DT&CRO Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 383930 trades above its calculated fair value: price 1,918 KRW, fair value 1,163 KRW, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 383930?
No. The price is what the market pays today (1,918 KRW); the fair value is what the company's own numbers justify (1,163 KRW). For DT&CRO Co. Ltd. the two are 755.37 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DT&CRO Co. Ltd. worth?
The market values DT&CRO Co. Ltd. at about 24.5B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 1,918 KRW; our models calculate a fair value of 1,163 KRW per share.
What do the bullish and bearish scenarios say about 383930?
Our models span a range for DT&CRO Co. Ltd.: cautious scenario 867.64 KRW, base 1,163 KRW, optimistic 1,735 KRW per share (as of Oct 3, 2026, price 1,918 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DT&CRO Co. Ltd. (383930)?
Balance-sheet figures for DT&CRO Co. Ltd. (as of Oct 3, 2026): return on equity −105.1%, debt of 0.51 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 383930 from its 52-week high?
DT&CRO Co. Ltd. trades at 1,918 KRW, about 49% below its 52-week high of 3,745 KRW and 32% above the low of 1,450 KRW (as of Oct 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,163 KRW is for.
Which stocks are comparable to DT&CRO Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DT&CRO Co. Ltd. stock attractive at the current price?
The data as of Oct 3, 2026: price 1,918 KRW, calculated fair value 1,163 KRW (−39%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 383930 calculated?
We run DT&CRO Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,163 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. DT&CRO Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DT&CRO Co. Ltd. (383930)?
The closing price on Oct 6, 2026 was 1,918 KRW. Our model-based fair value is 1,163 KRW, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DT&CRO Co. Ltd. right now?
The price sits above even our optimistic bull case (1,735 KRW). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (867.64 KRW to 1,735 KRW) leaves room in how you read the outcome.
Key figures of DT&CRO Co. Ltd.
How large is the market capitalisation of DT&CRO Co. Ltd. (383930)?
The market capitalisation of DT&CRO Co. Ltd. is 24.5B KRW (≈ $18.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DT&CRO Co. Ltd. (383930)?
The price-to-sales ratio of DT&CRO Co. Ltd. is 0.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of DT&CRO Co. Ltd. (383930)?
The net margin of DT&CRO Co. Ltd. is −5.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DT&CRO Co. Ltd. (383930)?
The return on equity (ROE) of DT&CRO Co. Ltd. is −105% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DT&CRO Co. Ltd. (383930)?
On an EBIT basis the return on assets of DT&CRO Co. Ltd. is −3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DT&CRO Co. Ltd. (383930)?
The operating margin of DT&CRO Co. Ltd. is −58.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DT&CRO Co. Ltd. (383930)?
Revenue at DT&CRO Co. Ltd. is growing +12.3% versus a year earlier (3y avg +2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DT&CRO Co. Ltd. (383930)?
Earnings per share at DT&CRO Co. Ltd. are growing −93.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does DT&CRO Co. Ltd. (383930) generate?
The free cash flow of DT&CRO Co. Ltd. is −14.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DT&CRO Co. Ltd. (383930) carry?
The net debt of DT&CRO Co. Ltd. is 33.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DT&CRO Co. Ltd. in the live analysis
One click puts DT&CRO Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
